Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

This trial (NICE-CC) tests a combination of two immunotherapy drugs — iparomlimab and tuvonralimab — along with chemotherapy as a treatment given before surgery for women with locally advanced cervical cancer. The goal is to shrink the tumor before the operation and improve long-term outcomes. **You may be eligible if...** - You are 18–70 years old with locally advanced cervical cancer (stages IB3, IIA2, or IIIC1r) - Your cancer is squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma confirmed by biopsy - You have not received any prior cancer treatment for this condition - Your blood counts and organ function meet the required levels - You have a measurable tumor **You may NOT be eligible if...** - You have previously had any cancer treatment - You have an active autoimmune condition requiring systemic therapy - You are currently enrolled in another clinical trial - You have had another cancer in the last 3 years - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.